Coeptis Therapeutics Holdings, Inc.

For the period ended Sep 30, 2025. Filed Nov 14, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 14, 2025

ZSQR$2.30-17.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Unaudited Condensed Consolidated Statements of Operations

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

	Three Months Ended		Nine Months Ended
	September 30, 2025	September 30, 2024	September 30, 2025	September 30, 2024
SALES
Sales	$237,441	$–	$500,996	$–
Total sales	237,441	–	500,996	–
Cost of goods	45,155	–	135,468	–
Gross profit	192,286	–	365,528	–
COST OF OPERATIONS
Research and development expense	587,279	811,784	964,247	1,987,670
Salary expense	355,516	378,740	1,237,474	1,283,198
Amortization expense	250,000	250,000	750,000	750,000
Professional services expense	1,062,352	431,304	6,363,539	2,476,392
Stock based compensation expense	213,035	96,888	1,001,787	805,347
General and administrative expenses	201,132	173,073	998,707	584,667
Selling and marketing expense	–	–	105,000	5,000
Total cost of operations	2,669,314	2,141,789	11,420,754	7,892,274
LOSS FROM OPERATIONS	(2,477,028)	(2,141,789)	(11,055,226)	(7,892,274)
OTHER (EXPENSE) INCOME
Interest expense	(62,610)	(50,926)	(201,889)	(317,487)
Other (expense) income, net	151,993	51,558	(75,053)	146,246
Unrealized loss on marketable securities	(568,868)	–	(178,302)	–
Loss on write down of assets	–	(37,257)	–	(37,257)
Change in fair value of derivative liabilities	57,750	349,500	856,180	235,125
TOTAL OTHER (EXPENSE) INCOME, net	(421,735)	312,875	400,936	26,627
LOSS BEFORE INCOME TAXES	(2,898,763)	(1,828,914)	(10,654,290)	(7,865,647)
PROVISION FOR INCOME TAXES	–	–	–	–
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	(2,739,403)	(1,732,592)	(10,339,146)	(7,763,546)
NET LOSS ATTRIBUTABLE TO NON-CONTROLLING INTERESTS	(159,360)	(96,322)	(315,144)	(102,101)
NET LOSS	$(2,898,763)	$(1,828,914)	$(10,654,290)	$(7,865,647)
LOSS PER SHARE
Loss per share, basic and fully diluted	$(0.58)	$(0.05)	$(2.69)	$(0.21)
Weighted average number of common shares outstanding	4,745,089	39,806,505	3,847,777	37,640,436

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.